摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(4-fluorophenyl)-2-methylbutan-1-one

中文名称
——
中文别名
——
英文名称
1-(4-fluorophenyl)-2-methylbutan-1-one
英文别名
(S)-2-Methyl-4'-fluorbutyrophenon
1-(4-fluorophenyl)-2-methylbutan-1-one化学式
CAS
——
化学式
C11H13FO
mdl
——
分子量
180.222
InChiKey
ZXOUVAPVBSWUDF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    13
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.36
  • 拓扑面积:
    17.1
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

  • 作为产物:
    描述:
    对氟苯甲酸仲丁基锂碘甲烷四氢呋喃正己烷环己烷 为溶剂, 反应 0.5h, 以71%的产率得到4-氟-2-甲基苯甲酸
    参考文献:
    名称:
    The First Regioselective Metalation and Functionalization of Unprotected 4-Halobenzoic Acids
    摘要:
    By treatment with s-BuLi, s-BuLi/TMEDA, or t-BuLi at similar to-78 degreesC, 4-fluoro- and 4-chlorobenzoic acids (1a,b) are metalated preferentially in the position adjacent to the carboxylate. A complete reversal in regioselectivity is observed for 1a when treated with LTMP; a sequential process involving a rapid intraaggregate lithiation through a quasi dianion complex "QUADAC" is postulated to explain the unusual reactivity of Me2S2 and I-2.
    DOI:
    10.1021/jo0483365
点击查看最新优质反应信息

文献信息

  • TRI-FUNCTIONAL UV-ABSORBING COMPOUNDS AND USE THEREOF
    申请人:Domschke Angelika Maria
    公开号:US20100168359A1
    公开(公告)日:2010-07-01
    Described herein are tri-functional compounds useful in the production of ophthalmic lenses. The compounds are composed of UV absorber having a polymerization initiator directly or indirectly bonded to the ultraviolet absorber, and an olefinic group directly or indirectly bonded to the ultraviolet absorber. Also described herein are polymers and ophthalmic lenses produced from the tri-functional compounds described herein.
    本文描述了一种在生产眼镜镜片中有用的三功能化合物。这些化合物由具有聚合引发剂直接或间接连接到紫外线吸收剂的UV吸收剂以及直接或间接连接到紫外线吸收剂的烯烃基组成。本文还描述了从所述三功能化合物制备的聚合物和眼镜镜片。
  • IMMUNOASSAY FOR PYRROLIDINOPHENONES
    申请人:RANDOX LABORATORIES LIMITED
    公开号:US20160097783A1
    公开(公告)日:2016-04-07
    The current invention provides an improved immunoassay for the detection and determination of pyrrolidinophenone based designer drugs in hair and biological fluids (urine, blood, and oral fluid). The generic immunoassay is underpinned by novel, sub-family-specific antibodies, which display surprising sensitivity. The invention further describes substrates comprising an antibody that is specific to compounds of the pyrrolidinophenone family. Also described are the novel immunogens from which the antibodies are derived and kits incorporating the antibodies of the current invention.
    该发明提供了一种改进的免疫测定方法,用于检测和测定基于哌哆利啶酮类设计药物在头发和生物液体(尿液、血液和口腔液)中的含量。通用的免疫测定方法基于新颖的、亚家族特异性抗体,显示出惊人的灵敏度。该发明进一步描述了包含特异于哌哆利啶酮类化合物的抗体的底物。还描述了从中获得抗体的新颖免疫原以及包含本发明抗体的试剂盒。
  • 18F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
    申请人:DEUTSCHES KREBSFORSCHUNGSZENTRUM
    公开号:US10016519B2
    公开(公告)日:2018-07-10
    The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer.
    本发明一般涉及放射性药物领域及其在核医学中作为示踪剂、成像剂和治疗前列腺癌各种疾病状态的用途。
  • 18F-TAGGED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER
    申请人:DEUTSCHES KREBSFORSCHUNGSZENTRUM
    公开号:US20170246327A1
    公开(公告)日:2017-08-31
    The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer.
  • INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO)
    申请人:InventisBio LLC
    公开号:US20220054486A1
    公开(公告)日:2022-02-24
    The present disclosure provides compounds of Formula (I). The compounds described herein may be useful in treating a disease associated with IDO, for example, cancer or an infectious disease (e.g., viral or bacterial infectious diseases). Also, provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.
查看更多